Comparison Workspace
Program Compare
Compare up to 6 HearScape records side by side across ownership, modality, stage, evidence, populations, trials, source support, and review notes.
1 Selected Records
URL-shareable comparison set.
| Field | PEDMARK by Fennec Pharmaceuticals Fennec Pharmaceuticals |
|---|---|
| Organization | Company: Fennec Pharmaceuticals |
| Program Type | Therapeutic |
| Modality | Small Molecule |
| Stage / Status | Marketed / Marketed |
| Review Status | checked · regulatory |
| Confidence | 98% |
| Target / Gene | — |
| Route / Mode | Intravenous |
| Indications | Cisplatin-Induced Hearing Loss; Hearing Loss |
| Population Tags | pediatric; cisplatin-ototoxicity |
| Geography | United States; European Union; United Kingdom |
| Trials | No registered trial ID listed. |
| Source Support | 3 structured sources · 3 URL-backed · regulatory, company |
| Last Reviewed | 2026-05-31 |
| Data Checks | No data flags |
| Mechanism | Systemic sodium thiosulfate reduces cisplatin-associated ototoxicity by chemically inactivating reactive platinum species after chemotherapy. |
| Notes | Only clearly commercialized hearing-loss-prevention drug in this set; marketed in the U.S. as PEDMARK and in Europe/UK as PEDMARQSI. |